The global IT and consulting company announced a long-term partnership with Pandorum Technologies, a biotechnology company working in the field of tissue engineering and regenerative medicine.
Together, the companies will focus on developing technologies that shorten time to market and maximize patient outcomes during regenerative medicine R&D and clinical trials. The partnership combines Wipro Holmes’ artificial intelligence (AI) capabilities with Pandorum’s expertise in regenerative medicine.
The initial focus of the collaboration will be “bio-engineered liquid cornea” and will extend to the entire product portfolio, including regenerative lung and liver tissue. Wipro Holmes’ AI-based decision support solution will provide insight into the potential outcomes of specific formulations, apply advanced algorithms to predict and improve treatment efficacy, and aid in the design of clinical studies.
On a consolidated basis, Wipro recorded a 1.3% increase in net profit to Rs 2,970 crore on a 3.3% increase in operating income to Rs 20,313.6 crore in Q3 FY22 compared to Q2 FY22. On a yearly basis, Wipro’s net profit fell 0.85% while revenue grew 29.63% in Q3 FY22.
Shares of Wipro fell 0.07% to Rs 587.35 on BSE. Wipro is a global leader in information technology, consulting and business process services.
Powered by Capital Market – Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)